160 HEALTH

2656
2.6108.90% ( -0.255 )
Delay Closed: Nov 16, 16:08:11

Overview

160 HEALTH (2656)

160 Health International Limited wholesales and retails pharmaceutical and healthcare products in China. Thedevelops Healthcare 160 Platform, an online healthca...

Open
2.910
High
2.935
Low
2.590
Prev. Close
2.865
Volume
19.55M
Turnover
52.81M
Avg Price
2.701
Bid/Ask Ratio
-54.93%
Amplitude
12.04%
52wk High
158.400
Volume Ratio
5.16
Turnover Ratio
5.63%
52wk Low
2.105
HK Mkt Cap
906.30M
Market CapHKD
906.30M
P/ETTM
Loss
P/EDynamic
184.18
P/EStatic
--
EPSTTM
-0.172
EPSDynamic
0.0142
EPSStatic
--
BVPS
0.79
P/B
3.29
HK Shares
347.24M
Dividend YieldTTM
--
DividendTTM
--
Shares
347.24M
Min lot size
250
Currency
HKD

Daily Events

  1. Nov, 16

    Health 160 (2656.HK) spiked then faded to HK$2.605, down 9.08% from HK$2.865, opening at HK$2.910 near the session high and sliding to HK$2.590 in the afternoon session on 19.3 million shares. The pullback follows a 22.57% advance driven by its first AI-computing order and Barclays lifting its stake to 9.8%, with the stock giving back 17.08% this week, while an earlier proposal to change auditors had already triggered a one-day 12% drop. Q2 2026 revenue fell 11.67% year on year to HK$184.1 million, yet net profit rose 131.12% to HK$1.23 million and operating income 222.28% to HK$3.21 million. The shares trade below MA20 of HK$2.825 and MA60 of HK$5.322, down 95.56% year to date, 98.36% below the 52-week high of HK$158.4 and only 23.75% above the October 21 low of HK$2.105. Revenue contraction still limits how far profit improvement carries into the share price.

  2. Nov, 13

    After rallying 22.57% last week, 160 Health reversed intraday and closed 6.4% lower at HK$2.865, tagging HK$3.080 in the morning before sliding to HK$2.705 in the afternoon on 41.77 million shares worth about HK$122 million and a 12.03% turnover rate, as profit-taking outweighed Barclays lifting its stake to 9.8%. Fundamentals cut against the tape: Q2 2026 revenue fell 11.67% year on year to HK$184.1 million, yet net profit rose 131.12% to HK$1.23 million, operating income jumped 222.28% to HK$3.21 million and EPS gained 125.69% to HK$0.0035. The price position remains depressed, down 95.12% year to date and 98.19% below the 52-week high of HK$158.4, with the close just above the MA20 of HK$2.818 but far under the MA60 of HK$5.442. Though the October 21 low of HK$2.105 has not been retested, and the RMB42 million AI computing contract remains a business thread.

  3. Nov, 12

    Health 160 fell 7.4% to HK$3.060 in a spike-and-fade session that opened at HK$3.300 and slid from the intraday high of HK$3.330 to the session low at the close, on HK$130 million turnover and an 11.68% turnover rate; the drop follows last week's 22.57% gain, when Barclays lifted its stake to 9.8%, while an earlier proposal to change auditors had already knocked the shares 12% in one day. Q2 2026 revenue of HK$184.1 million fell 11.67% year on year, yet net profit of HK$1.23 million rose 131.12% and operating income gained 222.28%, leaving a net margin of just 0.67% and improvement off a very low base. The price sits awkwardly: down 94.78% year to date and 98.07% below the 52-week high of HK$158.40, though 45.37% above the HK$2.105 low and above the MA20 of HK$2.80, still far under the MA60 of HK$5.555, with price-to-book at 3.86x. A RMB42 million AI computing contract signed in October remains the narrative anchor.

  4. Nov, 11

    Health 160 International reversed an early gain, touching HK$3.645 at 10:19 BJT before sliding through the afternoon to HK$3.285 at 15:55 and closing at HK$3.325, down 2.9% on a 16.8% turnover rate, as investors booked profits on the prior week's 22.57% rally driven by Barclays raising its stake to 9.8%, while the earlier proposal to change auditors still weighed. Q2 2026 revenue fell 11.67% yoy to HK$184.1 million, yet net profit rose 131.12% to HK$1.23 million on a thin 0.67% net margin, with operating profit up 222.28% to HK$3.21 million. The stock sits above its MA20 of HK$2.788 but far below the MA60 of HK$5.67, down 94.34% year-to-date, 97.9% below the March 17 high of HK$158.4 and 57.7% above the October 21 low of HK$2.105, with a PB of 4.19. Still, the first RMB42 million AI computing order and Barclays' 9.8% holding remain near-term references.

  5. Nov, 9

    Health 160 opened higher, dipped to HK$3.300, spiked to HK$3.740 by 11:31 BJ, then faded through the afternoon to HK$3.45, down about 2.3% from the prior close of HK$3.53 on HK$220 million turnover and an 18.1% turnover rate. Barclays raised its stake to 9.8% through purchases at roughly HK$3.18 and HK$3.26 a share, with southbound holdings up nearly 22%, flows that earlier drove a 14%-plus single-day jump and a 22.57% weekly gain, though the proposed change of auditor triggered a 12% slide and intraday swings of +6% and -6%. Q2 revenue fell 11.67% yoy to HK$184.1 million while net profit rose 131% to HK$1.23 million and operating income 222% to HK$3.21 million. The stock sits 97.8% below its 52-week high of HK$158.4 and down 94.1% YTD, above MA20 of 2.747 but far under MA60 of 5.909, with negative PE and PB of 4.35. Though a 0.67% net margin leaves little earnings cushion.

News